Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
DaVita (GB:0I7E)
LSE:0I7E
DaVita (0I7E) Share Price & Analysis
0 Followers
0I7E Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$71.57 - $141.39
Previous Close$139.15
Volume952.00
Average Volume (3M)3.21K
Market Cap
$12.26B
Enterprise Value$24.67B
Total Cash (Recent Filing)$391.67M
Total Debt (Recent Filing)$11.12B
Price to Earnings (P/E)18.8
Beta0.62
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.41
Shares Outstanding87,700,000
10 Day Avg. Volume15
30 Day Avg. Volume3,207
Standard Deviation0.10
R-Squared0.25
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.96
Price to Sales (P/S)3.27
Price to Cash Flow (P/CF)6.30
P/FCF Ratio8.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit1.21
Enterprise Value/Ebitda14.27
Forecast
1Y Price Target
$140.00Price Target Upside-1.80% Downside
Rating ConsensusHold
Number of Analyst Covering5
DaVita News
PremiumMarket News
SPY ETF Update, 5/3/2024 
PremiumPress Releases
DaVita Inc. 1st Quarter 2024 Results
PremiumCompany Announcements
DaVita Welcomes New Board Member and Committee Participant
Bulls Say, Bears Say
Bulls Say
Efficiency And GrowthCost savings and revenue cycle management strategies are expected to contribute to higher year-over-year growth.
Financial PerformanceAdjusted Operating Income was 8% above consensus, reflecting better revenues and margins.
Revenue GrowthRevenue per treatment to grow 2.5-3% year over year in 2024, with a significant part coming from rate increases.
Bears Say
Financial ForecastEstimated loss of $37m of EBITDA in 2025 for DaVita Inc. due to the new CMS rates.
Regulatory ChangesSurprise hit to dialysis buried in CMS Final Rates for 2025 MA and Part D could impact DaVita Inc.'s revenues.
Stock ValuationApproximate $3.49 impact to the share price based on the 2025E P/E ratio due to CMS rate changes.
---
0I7E FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest share price was $71.56 and its highest was $141.39 in the past 12 months.
What is DaVita’s market cap?
Currently, no data Available
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Aug 01, 2024 which is in 89 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on May 02, 2024. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.948 by $0.432.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Overvalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DaVita have?
DaVita has 87,700,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $2.38 in its last earnings report, beating expectations of $1.948. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of DaVita?
Among the largest hedge funds holding DaVita’s share is Berkshire Hathaway Inc. It holds DaVita’s shares valued at 4B.
---
DaVita Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$140.00 (-1.80% Downside)
$140.00 (-1.80% Downside)
Blogger Sentiment
Bullish
GB:0I7E Sentiment 92%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.01%
12-Months-Change
Fundamentals
Return on Equity
78.21%
Trailing 12-Months
Asset Growth
-0.34%
Trailing 12-Months
Company Description
DaVita
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
---
0I7E Earnings Call
Q1 2024
0:00 / 0:00
---
0I7E Revenue Breakdown
95.34% U.S. dialysis
4.66% Ancillary services
---
0I7E Stock 12 Months Forecast
Average Price Target
$140.00
▼(-1.80% Downside)
Technical Analysis
Best Analysts Covering 0I7E
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-41.94%
reiterated a sell rating 3 months ago
Copying Kevin Fischbeck's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -41.94% per trade.
---